{
  "resourceType": "ResearchStudy",
  "id": "ExampleStudyRAAINBOW",
  "meta": {
    "profile": [
      "https://www.vision-zero-oncology.de/fhir/StructureDefinition/clinical-study"
    ]
  },
  "identifier": [
    {
      "system": "http://clinicaltrials.gov",
      "value": "NCT03240627"
    }
  ],
  "title": "Double-blind, Vehicle-controlled, Randomised, Multi-centre Study to Evaluate the Efficacy and Safety of LH-8 Cutaneous Solution in Children and Adolescents With Moderate to Severe Scalp Alopecia Areata.",
  "status": "completed",
  "primaryPurposeType": {
    "coding": [
      {
        "code": "treatment",
        "system": "http://terminology.hl7.org/CodeSystem/research-study-prim-purp-type"
      }
    ]
  },
  "phase": {
    "coding": [
      {
        "code": "phase-2-phase-3",
        "system": "http://terminology.hl7.org/CodeSystem/research-study-phase",
        "display": "Phase 2/Phase 3"
      }
    ]
  },
  "category": [
    {
      "coding": [
        {
          "code": "C98388",
          "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "display": "Interventional Study"
        }
      ]
    },
    {
      "coding": [
        {
          "code": "C46079",
          "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "display": "Randomized Controlled Clinical Trial"
        }
      ]
    },
    {
      "coding": [
        {
          "code": "C15228",
          "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "display": "Double Blind Study"
        }
      ]
    },
    {
      "coding": [
        {
          "code": "C142743",
          "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "display": "Unequal Randomization"
        }
      ]
    }
  ],
  "focus": [
    {
      "coding": [
        {
          "code": "C1909",
          "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
          "display": "Pharmacologic Substance"
        }
      ]
    }
  ],
  "condition": [
    {
      "coding": [
        {
          "code": "68225006",
          "system": "http://snomed.info/sct",
          "display": "Alopecia areata (disorder)"
        }
      ]
    }
  ],
  "location": [
    {
      "coding": [
        {
          "code": "DE",
          "system": "urn:iso:std:iso:3166",
          "display": "Germany"
        }
      ]
    },
    {
      "coding": [
        {
          "code": "FR",
          "system": "urn:iso:std:iso:3166",
          "display": "France"
        }
      ]
    }
  ],
  "period": {
    "start": "2018-03-01",
    "end": "2022-03-17"
  },
  "principalInvestigator": {
    "reference": "Practitioner/example"
  },
  "site": [
    {
      "reference": "Organization/Charite-dermatology"
    },
    {
      "reference": "Organization/Sabouraud-Center"
    },
    {
      "reference": "Organization/Diagnostic-consulting-center-XXIV-Sofia"
    },
    {
      "reference": "Organization/SC-Centrul-Medical-Sana-SRL"
    }
  ],
  "arm": [
    {
      "name": "Experimental: LH-8 cutaneous solution",
      "type": {
        "coding": [
          {
            "code": "C174266",
            "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "display": "Investigational Arm"
          }
        ]
      },
      "description": "LH-8 cutaneous solution (0.126 mL per spray) applied to the whole scalp"
    },
    {
      "name": "Placebo Comparator: Placebo cutaneous solution",
      "type": {
        "coding": [
          {
            "code": "C174226",
            "system": "http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl",
            "display": "Control Arm"
          }
        ]
      },
      "description": "Placebo cutaneous solution (0.126 mL per spray) applied to the whole scalp"
    }
  ],
  "objective": [
    {
      "name": "Relative change in scalp alopecia areata severity scores (SALT) from baseline value to be assessed after 24 weeks of treatment. [ Time Frame: 24 weeks treatment ] Visual assessment and global standardised scalp photographs for SALT evaluation.",
      "type": {
        "coding": [
          {
            "code": "primary",
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type"
          }
        ]
      }
    },
    {
      "name": "Absolute change in SALT score from baseline at the end of 24 weeks' treatment period. [ Time Frame: 24 weeks treatment ]",
      "type": {
        "coding": [
          {
            "code": "secondary",
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type"
          }
        ]
      }
    },
    {
      "name": "Proportion of the responders, i.e. subjects achieving at least a 40% relative reduction in SALT score from baseline at the end of 24 weeks' treatment period. [ Time Frame: 24 weeks treatment ]",
      "type": {
        "coding": [
          {
            "code": "secondary",
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type"
          }
        ]
      }
    },
    {
      "name": "Adverse events [ Time Frame: 48 weeks ]",
      "type": {
        "coding": [
          {
            "code": "secondary",
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type"
          }
        ]
      }
    },
    {
      "name": "General physical examination findings, including irritation of eyes and skin [ Time Frame: 24 weeks treatment ]",
      "type": {
        "coding": [
          {
            "code": "secondary",
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type"
          }
        ]
      }
    },
    {
      "name": "Visual assessment and global standardised scalp photographs for SALT evaluation. [ Time Frame: After 12 and 24 weeks treatment ]",
      "type": {
        "coding": [
          {
            "code": "secondary",
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type"
          }
        ]
      }
    },
    {
      "name": "Evaluation of duration of treatment effect in responders, measured as relative SALT score changes from Visit 3 (end of treatment) after 12 weeks (Visit 4) and 24 weeks (Visit 5) of treatment-free period. (Visual assessment and global standardised scalp photographs for SALT evaluation.)",
      "type": {
        "coding": [
          {
            "code": "secondary",
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type"
          }
        ]
      }
    },
    {
      "name": "Assessment of treatment effect on hair follicles in non-alopecic areas by quantifying the number of new alopecic areas. [ Time Frame: 24 weeks treatment ]",
      "type": {
        "coding": [
          {
            "code": "secondary",
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type"
          }
        ]
      }
    },
    {
      "name": "Assessment of the rate of spontaneous hair regrowth. [ Time Frame: For 6-12 months ]",
      "type": {
        "coding": [
          {
            "code": "secondary",
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type"
          }
        ]
      }
    },
    {
      "name": "Assessment of the rate of spontaneous hair regrowth in placebo treated subjects with alopecia areata active for 6-12 months compared to those with alopecia areata active for more than 12 months. (Visual assessment and global standardised scalp photographs for SALT evaluation).",
      "type": {
        "coding": [
          {
            "code": "secondary",
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type"
          }
        ]
      }
    },
    {
      "name": "Absolute and relative change from baseline in Children's Dermatology Life Quality Index (CDLQI) scores. [ Time Frame: 48 weeks ]",
      "type": {
        "coding": [
          {
            "code": "secondary",
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type"
          }
        ]
      }
    },
    {
      "name": "Change in percentage of subjects from baseline by the severity banding CDLQI scores. [ Time Frame: 48 weeks ]",
      "type": {
        "coding": [
          {
            "code": "secondary",
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type"
          }
        ]
      }
    },
    {
      "name": "Percentages of subjects by EuroQol Five Dimensions Youth Questionnaire (EQ-5D-Y) dimensions and levels at Visits 1-5. [ Time Frame: 48 weeks ]",
      "type": {
        "coding": [
          {
            "code": "secondary",
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type"
          }
        ]
      }
    },
    {
      "name": "Absolute and relative change of the EQ-Visual Analogue Scale (EQ-VAS) scores from baseline [ Time Frame: 48 weeks ]",
      "type": {
        "coding": [
          {
            "code": "secondary",
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type"
          }
        ]
      }
    },
    {
      "name": "Evaluation of the Paediatric Alopecia Areata Patient Benefit Index (PAAPBI) scores at Visits 1 to 5. [ Time Frame: 48 weeks ]",
      "type": {
        "coding": [
          {
            "code": "secondary",
            "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type"
          }
        ]
      }
    }
  ]
}
